Imfinzi plus tremelimumab significantly improved overall survival in liver cancer
The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib
The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
Equity raise to finance growth and investments in the biological space
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations
This is a virtual event and the theme is `Transforming Healthcare beyond Covid’
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
Subscribe To Our Newsletter & Stay Updated